Podcast

Model-informed drug development (MIDD) capitalizes on past data points with predictive modeling to accelerate timelines and address challenges earlier. It also presents a slew of other potential advantages, such as shrinking the data-access gap between large pharma and small biotechs, and reducing study subjects in both nonclinical and clinical studies. So, what does this mean for the drug development industry as we know it? What separates "thoughtful acceleration" from "careless" acceleration? And why isn’t everyone using MIDD?

Host Lisa Sanford is joined by Patrick Smith, former SVP, Translational Science, at Certara, as they unpack the innovation of MIDD, its ongoing potential, and resulting shifts in the industry.

Host Lisa Sanford is joined by Neil Spooner (PCSIG), Katty Wan (Pfizer), Enaksha Wickremsinhe (Gates Medical Research Institute), and Jeff Plomley (Altasciences) to discuss microsampling and the role it plays in a patient-centric sampling approach.

With reduced sample volume, as well as the ability to provide additional options and convenience to patients, this episode showcases the “big” potential and impact of this innovative “small” technique. From training, logistical, and implementation challenges, to regulations and device dependency, learn more about the building momentum in both bioanalytical and clinical applications.

Learn about the multiple benefits that incorporating a multi-site approach can provide in early-phase clinical research, the “red and green flags” to look out for when working with a CRO, the importance of the “non-data stuff.”

Host Lisa Sanford is joined by Kat Connors, Director, Multi-Site Clinical Trial and Strategic Operations at Altasciences, as they discuss the momentum growing behind using a multi-site strategy, with a notable uptick in demand in the last few years. With multi-site solutions enabling access to more robust trial data, access to an expanded patient network, the opportunity to simultaneously work with specialty and healthy population branches, as well as improved trial efficiency, there is certainly more than one reason to tune in to this episode and hear more from their conversation!